AAPS PharmSciTech

, Volume 12, Issue 2, pp 610–619 | Cite as

A Kinetic Study of the Polymorphic Transformation of Nimodipine and Indomethacin during High Shear Granulation

  • Zhen Guo
  • Mingxin Ma
  • Tianyi Wang
  • Di Chang
  • Tongying Jiang
  • Siling Wang
Research Article

Abstract

The objective of the present study was to investigate the mechanism, kinetics, and factors affecting the polymorphic transformation of nimodipine (NMD) and indomethacin (IMC) during high shear granulation. Granules containing active pharmaceutical ingredient, microcrystalline cellulose, and low-substituted hydroxypropylcellulose were prepared with ethanolic hydroxypropylcellulose solution, and the effects of independent process variables including impeller speed and granulating temperature were taken into consideration. Two polymorphs of the model drugs and granules were characterized by X-ray powder diffraction analysis and quantitatively determined by differential scanning calorimetry. A theoretical kinetic method of ten kinetic models was applied to analyze the polymorphic transformation of model drugs. The results obtained revealed that both the transformation of modification I to modification II of NMD and the transformation of the α form to the γ form of IMC followed a two-dimensional nuclei growth mechanism. The activation energy of transformation was calculated to be 7.933 and 56.09 kJ·mol−1 from Arrhenius plot, respectively. Both the granulating temperature and the impeller speed affected the transformation rate of the drugs and, in particular, the high shear stress significantly accelerated the transformation process. By analyzing the growth mechanisms of granules in high-shear mixer, it was concluded that the polymorphic transformation of NMD and IMC took place in accordance with granule growth in a high-shear mixer.

KEY WORDS

differential scanning calorimetry granule growth mechanism high shear granulation polymorphic transformation kinetic X-ray powder diffraction 

Notes

ACKNOWLEDGMENT

The authors would like to thank Collette N.V, Belgium, for supplying the MicroGral® high-shear mixers and for their logistic and technical support. This work was supported by the National Basic Research Program of China (973 Program; No.2009CB930300) and Major National Platform for Innovative Pharmaceuticals (No. 2009ZX09301-012).

References

  1. 1.
    Haleblian J, McCrone W. Pharmaceutical applications of polymorphism. J Pharm Sci. 1969;58:911–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Grunenberg A, Keil B, Henck JO. Polymorphism in binary mixture, as exemplified by nimodipine. Int J Pharm. 1995;118:11–21.CrossRefGoogle Scholar
  3. 3.
    Yamamoto H. 1-Acyl-indoles. II. A new syntheses of 1-(p-chlorobenzoyl)-5-methoxy-3-indolylacetic acid and its polymorphism. Chem Pharm Bull. 1968;16:17–9.PubMedGoogle Scholar
  4. 4.
    Joshi V. Physical transformations in solvated pharmaceuticals. Ph.D. Dissertation, Purdue University, West Lafayette, IN; 1998.Google Scholar
  5. 5.
    Wu T, Yu L. Origin of enhanced crystal growth kinetics near T g probed with indomethacin polymorphs. J Phys Chem B. 2006;110:15694–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaneniwa N, Otsuka M, Hayashi T. Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. Chem Pharm Bull. 1985;33:3447–55.PubMedGoogle Scholar
  7. 7.
    Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev. 2001;48:91–114.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang GG, Law D, Schmitt EA, Qiu YH. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev. 2004;56:371–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Schæfer T, Holm P, Kristensen G. Melt pelletization in a high shear mixer. I. Effects of process variables and binder. Acta Pharm Nord. 1992;4:133–40.Google Scholar
  10. 10.
    Wang S, Ye G, Heng PWS, Ma M. Investigation of high shear wet granulation processes using different parameters and formulation. Chem Pharm Bull. 2008;56:22–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Schæfer T, Mathiesen C. Melt pelletization in a high shear mixer. VII. Effects of product temperature. Int J Pharm. 1996;134:105–17.CrossRefGoogle Scholar
  12. 12.
    Voinovich D, Campsi B, Moneghini M, Vincenzi C, Phan-Tan-Luu R. Screening of high shear mixer melt granulation process variables using an asymmetrical factorial design. Int J Pharm. 1999;190:73–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Keningley ST, Knight PC, Marson AD. An investigation into the effects of binder viscosity on agglomeration behaviour. Powder Technol. 1997;91:95–103.CrossRefGoogle Scholar
  14. 14.
    Schaefer T, Holm P, Kristensen G. Melt pelletization in a high shear mixer. III. Effects of lactose quality. Acta Pharm Nord. 1992;4:245–52.Google Scholar
  15. 15.
    Pan X, Julian T, Augsburger L. Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethacin. Drug Dev Ind Pharm. 2008;34:221–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Pan X, Julian T, Augsburger L. Quantitative measurement of indomethacin crystallinity in indomethacin-silica gel binary system using differential scanning calorimetry and X-ray powder diffractometry. AAPS Pharm Sci Tech. 2006;7:E72–8.CrossRefGoogle Scholar
  17. 17.
    He Z, Zhong D, Chen X, Liu X, Tang X, Zhao L. Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci. 2004;21:487–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Barmpalexis P, Kachrimanis K, Georgarakis E. Solid dispersions in the development of a nimodipine floating tablet formulation and optimization by artificial neural networks and genetic programming. Eur J Pharm Biopharm. 2011;77:122–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Murali Mohan Babu GV, Prasad CHDS, Ramana Murthy KV. Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine. Int J Pharm. 2002;234:1–17.PubMedCrossRefGoogle Scholar
  20. 20.
    Otsuka M, Kato F, Matsuda Y, Ozaki Y. Comparative determination of polymorphs of indomethacin in powders and tablets by chemometrical near-infrared spectroscopy and X-ray powder diffractometry. AAPS Pharm Sci Tech. 2003;4:1–12.Google Scholar
  21. 21.
    Aceves-Hernadez JM, Nicolás-Vázquez I, Aceves FJ, Hinojosa-Torres J, Paz M, Castaño VM. Indomethacin polymorphs: experimental and conformational analysis. J Pharm Sci. 2009;98:2448–63.CrossRefGoogle Scholar
  22. 22.
    Hancock JD, Sharp JH. Method of comparing solid-state kinetic data and its application to the decomposition of kaolinite, brucite, and BaCO3. J Am Ceram Soc. 1972;55:74–7.CrossRefGoogle Scholar
  23. 23.
    Criado JM, Morales J, Rives V. Computer kinetic analysis of simultaneously obtained TG and DTG curves. J Thermal Anal. 1978;14:221–8.CrossRefGoogle Scholar
  24. 24.
    Hirayama F, Wang Z, Uekama K. Effect of 2-hydroxypropyl-β-cyclodextrin on crystallization and polymorphic transition of nifedipine in solid state. Pharm Res. 1994;11:1766–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Grunenberg A, Henck JO, Siesler HW. Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int J Pharm. 1996;129:147–58.CrossRefGoogle Scholar
  26. 26.
    Bauer-Brandl A. Polymorphic transitions of cimetidine during manufacture of solid dosage forms. Int J Pharm. 1996;140:195–206.CrossRefGoogle Scholar
  27. 27.
    Iveson SM, Litster JD. Growth regime map for liquid-bounded granules. AICHE J. 1998;44:1510–8.CrossRefGoogle Scholar
  28. 28.
    Tu W, Ingram A, Seville J, Hsiau S. Exploring the regime map for high-shear mixer granulation. Chem Eng J. 2009;145:505–13.CrossRefGoogle Scholar
  29. 29.
    Vonk P, Guillaume CPF, Ramaker JS, Vromans H, Kossen NWF. Growth mechanisms of high-shear pelletization. Int J Pharm. 1997;157:93–102.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2011

Authors and Affiliations

  • Zhen Guo
    • 1
  • Mingxin Ma
    • 2
  • Tianyi Wang
    • 1
  • Di Chang
    • 1
  • Tongying Jiang
    • 1
  • Siling Wang
    • 1
  1. 1.School of PharmacyShenyang Pharmaceutical UniversityShenyangPeople’s Republic of China
  2. 2.Shenyang Xingqi Pharmaceutical Co. Ltd.ShenyangPeople’s Republic of China

Personalised recommendations